Tucson, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Tucson, Arizona -

GW501516 (Cardarine) is a compound that acts as a PPARδ modulator. It is often grouped with sarms when it is discussed and sold on research sites but it would fall under a different category scientifically. It is often researched together with other sarms and various research products, thus the grouping and association amongst researchers. Pre-clinical studies determined that GW 501516 activates AMP-activated protein kinase and stimulates glucose uptake in skeletal muscle tissue as well as demonstrating capabilities to reverse metabolic abnormalities in obese subjects with pre-diabetic metabolic syndrome, most likely by stimulating fatty acid oxidation. It has been proposed as a potential treatment for obesity and related conditions as the combination has been shown to significantly increase exercise endurance in animal studies.

How it works: GW501516 is a selective agonist (activator) of the PPARδ receptor. It displays high affinity (Ki = 1 nM) and potency (EC50 = 1 nM) for PPARδ with > 1000 fold selectivity over PPARα and PPARγ.

In studies conducted on rats, the binding of GW501516 to PPARδ recruits the coactivator PGC-1a. The PPARδ/coactivator complex then in turn regulates the expression of proteins involved in energy expenditure. Furthermore, in rats treated with GW501516, there was increased fatty acid metabolism in skeletal muscle and protection against diet-induced obesity. In obese rhesus monkeys, GW501516 increased high-density lipoprotein (HDL) and lowered very-low-density lipoprotein (VLDL). The mechanism by which PPARδ agonists increase HDL appears to be a result of increased expression of the cholesterol transporter ABCA1.

Main research uses: The following are anecdotal analysis that have been determined over time by researchers on rats to find other benefits with GW-501516.

The main conclusion drawn by researchers from pre-clinical studies is the endurance benefit observed in mice. The compound itself was banned by the WADA and the NCAA due to the apparent advantages it could provide, which could potentially validate the findings or it could be precautionary on their part. Mice have shown to have quite drastic endurance increases.

The next main finding is that of fat loss. Pre-clinical studies made by researchers have found a strong capability in rats for fat loss and metabolism increases over short periods of time. The pre-clinical studies are often conducted between 4-12 weeks on rats with differing doses for testing. These are all accessible online on various websites.

One other substantial pre-clinical finding on rats is the ability to lower LDL (bad cholesterol), raise good cholesterol (HDL) as well as lowering blood pressure. These are all pre-clinical and anecdotal findings that are quite prevalent throughout the internet.

In conclusion, the pre-clinical data on GW 501516 is extremely promising and the compound has grown in interest for research over the years, with intrigue and interest in it’s structure and capability to be growing by the day.

https://www.youtube.com/watch?v=RQi96GghAfk

Umbrella Labs takes pride in the efficacy and quality of their research products, allowing a researcher to have the opportunity to obtain true and accurate findings on their research, unlike many other research companies who do not take the mindful approach of putting true and accurate research first. Umbrella Labs ensures that proper research results can be conducted and the researcher is always put first.

###

For more information about Umbrella Labs , contact the company here:

Umbrella Labs
Kristin McFadden
415-988-7551
kmcfadden@umbrella-labs.us
3280 E Hemisphere Loop
Tucson, AZ 85706